Correlation between esmolol usage in the acute phase of ischemic stroke and outcomes of patients undergoing intravenous thrombolysis

Figure 1 Kaplan-Meier 90-day survival curves. A: Kaplan-Meier 90-day survival curves for all patients undergoing intravenous thrombolysis (IT) for acute ischemic stroke (AIS). The 90-day survival rates in the esmolol-treated subgroup (76%) were non-significantly lower than those in the esmolol-untreated group (88%) (log-rank test; P = 0.077); B: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients without atrial fibrillation who underwent IT for AIS. The survival rates in the esmolol-treated subgroup (62%) were significantly lower than those in the esmolol-untreated subgroup (88%) (log-rank test; P = 0.009).

Figure 2 Kaplan-Meier 90-day survival curves. A: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients with atrial fibrillation who underwent intravenous thrombolysis (IT) for acute ischemic stroke (AIS). The survival rates were not significantly different between the esmolol-treated and esmolol-untreated subgroups (log-rank test; P = 0.807); B: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients with a history of hypertension who underwent IT for AIS. The survival rates were not significantly different between the esmolol-treated and esmolol-untreated subgroups (log-rank test; P = 0.23); C: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients without a history of hypertension who underwent IT for AIS. The survival rates were not significantly different between the esmolol-treated and esmolol-untreated subgroups (log-rank test; P = 0.13).